Toray licenses TRK‑820 (Nalfurafine HCl) to Immunis for L‑dopa‑induced dyskinesia
- Immunis obtained exclusive rights to develop and commercialize the candidate in the United States, Canada, the EU and the EFTA.
- TRK‑820 (Nalfurafine Hydrochloride) is described as the world's first selective opioid kappa receptor agonist discovered by Toray.
- Immunis submitted an IND to the U.S. FDA in February 2026 to initiate a Phase I clinical trial for IMM02‑KORA.
- Deal terms include an upfront payment, development‑stage milestone fees, sales‑based milestone fees and royalties after launch.
Agreement
Toray has out‑licensed TRK‑820 (development code; generic name Nalfurafine Hydrochloride) to Immunis, which will develop and commercialize the candidate under the name IMM02‑KORA in the United States, Canada, the European Union and the European Free Trade Association. Financial terms include an upfront payment, milestone fees tied to development stages, and sales‑based milestone fees and royalties.
Candidate and mechanism
TRK‑820 is described as the world's first selective opioid kappa receptor agonist discovered by Toray. Immunis is advancing it as a therapeutic candidate targeting L‑dopa‑induced dyskinesia associated with Parkinson’s disease.
Regulatory status
In February 2026 Immunis submitted an Investigational New Drug application to the U.S. Food and Drug Administration to initiate a Phase I clinical trial.
Disease context
Toray cites WHO data showing global Parkinson’s disease prevalence roughly doubled over the prior 25 years; as of 2019 more than 8.5 million people were estimated to be living with PD. L‑dopa remains a common symptomatic treatment but long‑term use can be associated with complications including involuntary movements (dyskinesia), the indication IMM02‑KORA aims to treat.
Source: Toray
